Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec 8;82(1):112–117. doi: 10.1054/bjoc.1999.0886

Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues

R H N van Schaik 1, C D J Wierikx 1, M A Timmerman 1, M H Oomen 2, W M van Weerden 2, T H van der Kwast 3, G J van Steenbrugge 2, F H de Jong 1
PMCID: PMC2363208  PMID: 10638976

Abstract

The possible role of activin in the regulation of malignant prostatic growth was studied using RNAase protection assays of activin receptors, inhibin/activin subunits and follistatin mRNAs in the human prostatic carcinoma cell lines LNCaP-FGC, -R and -LNO, in human prostatic carcinoma xenografts and in human prostatic tissue. Activin receptor types IA (ActRIA), IB (ActRIB), IIA (ActRIIA) and IIB (ActRIIB) mRNAs were generally expressed in prostate pithelial cells, with significantly lower levels of ActRIB mRNA in prostate tumour aterial when compared to non-malignant tissue (P< 0.05; Mann–Whitney U -test). Inhibin/activin βA- and βB-subunit mRNA expression was also found in prostate tissue. Androgen-independent xenografts expressed significantly lower amounts of βB-subunit mRNA when compared to androgen-dependent xenografts (P< 0.05). While βB-subunit mRNA was expressed by LNCaP-FGC and -LNO cells, virtually no expression was found in the androgen-independent LNCaP-R line. Inhibin α-subunit mRNA levels were low or undetectable in all samples investigated. Follistatin mRNA was undetectable in LNCaP-sublines, while low levels were found in prostatic tissues. In androgen-independent LNCaP-R cells, activin inhibited cell growth in a dose-dependent manner. These results suggest that prostate tumour progression is accompanied by a decrease of the inhibitory effect of locally produced activin by either a decrease in the expression of activin βB-subunit mRNA or by a decrease of ActRIB mRNA levels. © 2000 Cancer Research Campaign

Keywords: activin receptor, activin, inhibin, follistatin, prostate cancer

Full Text

The Full Text of this article is available as a PDF (99.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cárcamo J., Weis F. M., Ventura F., Wieser R., Wrana J. L., Attisano L., Massagué J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin. Mol Cell Biol. 1994 Jun;14(6):3810–3821. doi: 10.1128/mcb.14.6.3810-3821.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dalkin A. C., Gilrain J. T., Bradshaw D., Myers C. E. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology. 1996 Dec;137(12):5230–5235. doi: 10.1210/endo.137.12.8940339. [DOI] [PubMed] [Google Scholar]
  3. Donaldson C. J., Mathews L. S., Vale W. W. Molecular cloning and binding properties of the human type II activin receptor. Biochem Biophys Res Commun. 1992 Apr 15;184(1):310–316. doi: 10.1016/0006-291x(92)91194-u. [DOI] [PubMed] [Google Scholar]
  4. Erba H. P., Gunning P., Kedes L. Nucleotide sequence of the human gamma cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes. Nucleic Acids Res. 1986 Jul 11;14(13):5275–5294. doi: 10.1093/nar/14.13.5275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Feng Z. M., Madigan M. B., Chen C. L. Expression of type II activin receptor genes in the male and female reproductive tissues of the rat. Endocrinology. 1993 Jun;132(6):2593–2600. doi: 10.1210/endo.132.6.7916681. [DOI] [PubMed] [Google Scholar]
  6. Gonzalez-Manchon C., Vale W. Activin-A, inhibin and transforming growth factor-beta modulate growth of two gonadal cell lines. Endocrinology. 1989 Sep;125(3):1666–1672. doi: 10.1210/endo-125-3-1666. [DOI] [PubMed] [Google Scholar]
  7. Hasenson M., Hartley-Asp B., Kihlfors C., Lundin A., Gustafsson J. A., Pousette A. Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r. Prostate. 1985;7(2):183–194. doi: 10.1002/pros.2990070208. [DOI] [PubMed] [Google Scholar]
  8. Hashimoto M., Kondo S., Sakurai T., Etoh Y., Shibai H., Muramatsu M. Activin/EDF as an inhibitor of neural differentiation. Biochem Biophys Res Commun. 1990 Nov 30;173(1):193–200. doi: 10.1016/s0006-291x(05)81040-x. [DOI] [PubMed] [Google Scholar]
  9. Hedger M. P., Drummond A. E., Robertson D. M., Risbridger G. P., de Kretser D. M. Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Mol Cell Endocrinol. 1989 Jan;61(1):133–138. doi: 10.1016/0303-7207(89)90198-6. [DOI] [PubMed] [Google Scholar]
  10. Hildén K., Tuuri T., Erämaa M., Ritvos O. Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor. Blood. 1994 Apr 15;83(8):2163–2170. [PubMed] [Google Scholar]
  11. Hoehn W., Schroeder F. H., Reimann J. F., Joebsis A. C., Hermanek P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82). Prostate. 1980;1(1):95–104. doi: 10.1002/pros.2990010113. [DOI] [PubMed] [Google Scholar]
  12. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Chu T. M., Mirand E. A., Murphy G. P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 Apr;43(4):1809–1818. [PubMed] [Google Scholar]
  13. Ilio K. Y., Sensibar J. A., Lee C. Effect of TGF-beta 1, TGF-alpha, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J Androl. 1995 Nov-Dec;16(6):482–490. [PubMed] [Google Scholar]
  14. Mason A. J., Niall H. D., Seeburg P. H. Structure of two human ovarian inhibins. Biochem Biophys Res Commun. 1986 Mar 28;135(3):957–964. doi: 10.1016/0006-291x(86)91021-1. [DOI] [PubMed] [Google Scholar]
  15. Massagué J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell. 1996 Jun 28;85(7):947–950. doi: 10.1016/s0092-8674(00)81296-9. [DOI] [PubMed] [Google Scholar]
  16. Mathews L. S. Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev. 1994 Jun;15(3):310–325. doi: 10.1210/edrv-15-3-310. [DOI] [PubMed] [Google Scholar]
  17. Mayo K. E., Cerelli G. M., Spiess J., Rivier J., Rosenfeld M. G., Evans R. M., Vale W. Inhibin A-subunit cDNAs from porcine ovary and human placenta. Proc Natl Acad Sci U S A. 1986 Aug;83(16):5849–5853. doi: 10.1073/pnas.83.16.5849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McPherson S. J., Thomas T. Z., Wang H., Gurusinghe C. J., Risbridger G. P. Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol. 1997 Sep;154(3):535–545. doi: 10.1677/joe.0.1540535. [DOI] [PubMed] [Google Scholar]
  19. Mellor S. L., Richards M. G., Pedersen J. S., Robertson D. M., Risbridger G. P. Loss of the expression and localization of inhibin alpha-subunit in high grade prostate cancer. J Clin Endocrinol Metab. 1998 Mar;83(3):969–975. doi: 10.1210/jcem.83.3.4640. [DOI] [PubMed] [Google Scholar]
  20. Risbridger G. P., Thomas T., Gurusinghe C. J., McFarlane J. R. Inhibin-related proteins in rat prostate. J Endocrinol. 1996 Apr;149(1):93–99. doi: 10.1677/joe.0.1490093. [DOI] [PubMed] [Google Scholar]
  21. Romijn J. C., Verkoelen C. F., Schroeder F. H. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate. 1988;12(1):99–110. doi: 10.1002/pros.2990120112. [DOI] [PubMed] [Google Scholar]
  22. Rubin S. J., Hallahan D. E., Ashman C. R., Brachman D. G., Beckett M. A., Virudachalam S., Yandell D. W., Weichselbaum R. R. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol. 1991 Jan;46(1):31–36. doi: 10.1002/jso.2930460108. [DOI] [PubMed] [Google Scholar]
  23. Thomas T. Z., Chapman S. M., Hong W., Gurusingfhe C., Mellor S. L., Fletcher R., Pedersen J., Risbridger G. P. Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. Prostate. 1998 Jan 1;34(1):34–43. doi: 10.1002/(sici)1097-0045(19980101)34:1<34::aid-pros5>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  24. Wang Q. F., Tilly K. I., Tilly J. L., Preffer F., Schneyer A. L., Crowley W. F., Jr, Sluss P. M. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology. 1996 Dec;137(12):5476–5483. doi: 10.1210/endo.137.12.8940374. [DOI] [PubMed] [Google Scholar]
  25. Zhang Z., Zhao Y., Batres Y., Lin M. F., Ying S. Y. Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun. 1997 May 19;234(2):362–365. doi: 10.1006/bbrc.1997.6649. [DOI] [PubMed] [Google Scholar]
  26. ten Dijke P., Franzén P., Yamashita H., Ichijo H., Heldin C. H., Miyazono K. Serine/threonine kinase receptors. Prog Growth Factor Res. 1994;5(1):55–72. doi: 10.1016/0955-2235(94)90017-5. [DOI] [PubMed] [Google Scholar]
  27. van Schaik R. H., Wierikx C. D., Looijenga L. H., Oosterhuis J. W., de Jong F. H. Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs. Br J Cancer. 1997;76(9):1191–1198. doi: 10.1038/bjc.1997.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. van Steenbrugge G. J., van Uffelen C. J., Bolt J., Schröder F. H. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol. 1991;40(1-3):207–214. doi: 10.1016/0960-0760(91)90184-7. [DOI] [PubMed] [Google Scholar]
  29. van Weerden W. M., de Ridder C. M., Verdaasdonk C. L., Romijn J. C., van der Kwast T. H., Schröder F. H., van Steenbrugge G. J. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol. 1996 Sep;149(3):1055–1062. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES